Therapy Areas: AIDS & HIV
Amytrx Therapeutics names new directors
8 November 2023 -

Amytrx Therapeutics, a US-based biopharmaceutical company specialising in the development of novel therapies for dermatology and inflammation, announced on Tuesday that it has added Dr Michael Howell and Dr Satish Joshi as its new directors.

Dr Howell has over 20 years of experience in allergy, autoimmunity, dermatology, inflammatory and oncology diseases. He has played an important role in various clinical trials and has published extensively on topics regarding dermatological and immunological conditions.

Dr Joshi has more than 25 years of experience in the peptide API business. He has been at the forefront of peptide product development throughout his career.

Dr Matthew A. Gonda, Amytrx Therapeutics CEO, said: "Amytrx Therapeutics is excited to welcome Dr. Howell and Dr. Joshi to our board of directors. Their exceptional scientific and business backgrounds align perfectly with our mission to bring transformative treatments to patients in need. Their contributions will be invaluable as we continue to advance our lead candidate, AMTX-100, and work towards its successful commercialisation."